Back to Search
Start Over
Rivaroxaban in clinical practice for atrial fibrillation with special reference to prothrombin time.
- Source :
-
Circulation journal : official journal of the Japanese Circulation Society [Circ J] 2014; Vol. 78 (3), pp. 763-6. Date of Electronic Publication: 2014 Jan 21. - Publication Year :
- 2014
-
Abstract
- Background: Prothrombin time (PT) distribution in Japanese nonvalvular atrial fibrillation (NVAF) patients under rivaroxaban therapy remains to be clarified.<br />Methods and Results: Between May 2012 and July 2013, 115 NVAF patients received rivaroxaban (PT was measured in 94; reagent: recombiplastin). In these patients, (1) PT values were distributed widely from patient to patient and from peak to trough, (2) the time-dependence was obscure with sampling at any time in the outpatient clinic, and (3) the incidence of adverse events was too low for analyzing the relation with PT.<br />Conclusions: We report the distribution of PT for Japanese NVAF patients under rivaroxaban therapy in real-world clinical practice.
- Subjects :
- Aged
Aged, 80 and over
Asian People
Female
Humans
Japan
Male
Middle Aged
Prospective Studies
Rivaroxaban
Atrial Fibrillation blood
Atrial Fibrillation drug therapy
Factor Xa Inhibitors administration & dosage
Morpholines administration & dosage
Prothrombin Time
Thiophenes administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1347-4820
- Volume :
- 78
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Circulation journal : official journal of the Japanese Circulation Society
- Publication Type :
- Academic Journal
- Accession number :
- 24451650
- Full Text :
- https://doi.org/10.1253/circj.cj-13-1380